Brand Name: ONDAMIN R COMBIPACK

Composition: Combipack of ranitidine injection IP ondansetron injection IP
Dosage Form: INJECTION (COMBI PACK)
Category: Anti-emetic & Anti-ulcer Combination
Packaging Type: 2 x 2 ML
Packaging: AMPULE

Brief Product Introduction:

ONDAMIN R COMBIPACK is a dual-action injectable therapy developed by **AstraEureka Pharmaceutical**, a reputed manufacturer of composition-based parenteral solutions. This combipack includes **Ondansetron 2 mg/ml** and **Ranitidine 25 mg/ml**, designed to provide both **antiemetic and anti-ulcer support** in one treatment set. Ondansetron is a 5-HT_3 receptor antagonist used to prevent nausea and vomiting due to chemotherapy, radiotherapy, and surgery. Ranitidine is an H_2 receptor blocker that reduces gastric acid secretion, protecting the gastrointestinal tract during emetogenic stress. This combination is particularly useful in pre- and post-operative care, cancer therapy protocols, and emergency care settings where nausea, vomiting, and acid reflux co-occur. Both drugs act synergistically to protect the GI tract and improve patient comfort and compliance.

Composition:

Part A (2 ml Ampoule):

- Ondansetron Hydrochloride IP
  Equivalent to Ondansetron……2 mg/ml
- Water for Injection IP……Q.S.

Part B (2 ml Ampoule):

- Ranitidine Hydrochloride IP
  Equivalent to Ranitidine……25 mg/ml
- Phenol IP……0.5% w/v
- Water for Injection IP……Q.S.

Key Ingredients

- **Ondansetron (2 mg/ml):** Selective serotonin 5-HT_3 receptor antagonist
- **Ranitidine (25 mg/ml):** H_2 receptor blocker reducing gastric acid
- **Phenol (0.5% w/v):** Preservative
- **Water for Injection:** Sterile solvent

Key Benefits:

1. Immediate relief from nausea and vomiting
2. Reduces gastric acidity and acid reflux symptoms

3. Dual protection in post-operative and chemotherapy care
4. Ideal for acute care, oncology, and ICU patients
5. Convenient combipack for quick administration

Indications:

1. Nausea and vomiting induced by chemotherapy or radiotherapy
2. Post-operative nausea and vomiting (PONV)
3. Acid peptic disorders and gastritis during emesis
4. Stress ulcers in critically ill patients
5. Supportive therapy in drug-induced emetogenic conditions

Directions for Use:

1. For intravenous or intramuscular administration
2. Administer Ondansetron first, followed by Ranitidine
3. Use aseptic techniques during preparation and injection
4. To be administered by qualified healthcare professionals only

Dosage and Administration:

1. **Part A – Ondansetron:**

- Adult dose: 4–8 mg IV/IM prior to chemotherapy or surgery
- May repeat every 8–12 hours as needed

2. **Part B – Ranitidine:**

- Adult dose: 25–50 mg IV slowly over 5 minutes
- Can be repeated every 6–8 hours depending on clinical need

3. Dosage should be adjusted based on patient's age, condition, and renal function.

Safety Information:

- Use under strict medical supervision
- Monitor liver function during Ondansetron therapy
- Caution in renal impairment for Ranitidine
- Not recommended for pediatric use without physician guidance
- Avoid mixing both injections in the same syringe

Mechanism of Action:

- **Ondansetron:** Blocks 5-HT_3 receptors in the chemoreceptor trigger zone (CTZ) and gastrointestinal tract, thereby preventing nausea and vomiting.
- **Ranitidine:** Competitively inhibits histamine at H_2 receptors on gastric parietal cells, reducing both basal and stimulated gastric acid secretion. Together, they address both the central emetic triggers and peripheral gastric irritation.

Contraindications:

1. Hypersensitivity to Ondansetron, Ranitidine, or any component of the formulation
2. History of QT prolongation or cardiac arrhythmia
3. Severe hepatic impairment (Ondansetron caution)
4. Acute porphyria (Ranitidine contraindication)

Side Effects:

1. Ondansetron: Headache, constipation, dizziness, fatigue
2. Ranitidine: Diarrhea, bradycardia (rare), rash, altered liver enzymes
3. Rare: Hypotension, allergic reactions, injection site irritation

Important Notice:

- ONDAMIN R COMBIPACK is intended for **hospital and emergency care** only
- Should not be self-administered
- Follow proper dosing intervals to avoid toxicity or inefficacy
- Monitor ECG in patients with cardiac conditions

Storage Condition:

1. Store below 25°C
2. Protect from light and moisture
3. Do not freeze
4. Use immediately after opening ampoule

Packing Information:

- Supplied in **2 x 2 ml Ampoules** (one each of Ondansetron and Ranitidine).
- Includes instructions for administration inside the pack.